Immediate Applicability (Tier 1)
These conditions share substantial pathophysiology with ME/CFS, documented in peer-reviewed literature. Translational findings have high-to-medium certainty.
1 Long COVID / Post-Acute Sequelae of SARS-CoV-2 (PASC)
Long COVID and ME/CFS share post-viral onset, exercise intolerance with delayed symptom exacerbation, autonomic dysfunction, and cognitive impairment, with a substantial proportion of Long COVID patients meeting activity-based case definitions also meeting ME/CFS diagnostic criteria (Jason and Dorri 2023).
1.2 Novel Translational Findings from ME/CFS
Plasma Cell Targeting (Daratumumab): Pilot study showed 60% response rate in ME/CFS when rituximab (B-cell depletion) failed (Fluge et al. 2025). This suggests long-lived plasma cells, not B cells, drive persistent autoantibody production. Implication for Long COVID: Patients with persistent symptoms despite viral clearance may benefit from plasma cell-directed therapy, particularly those with elevated GPCR autoantibodies.
Immunoadsorption for GPCR Autoantibodies: 70% rapid improvement during treatment in a pilot study (n=10) of ME/CFS patients with elevated \(\beta\) 2-adrenergic receptor autoantibodies, though only 30% sustained improvement at 6–12 months (Scheibenbogen et al. 2018). Implication for Long COVID: Autoantibody screening could identify subset likely to respond to immunoadsorption.
NAD+ Restoration with Nicotinamide Riboside: A 2025 Long COVID RCT (n=58; 20-week intervention) showed NR 2000 mg/day increased NAD+ levels 2.6–3.1\(\\times\) (Wu, Guzmán-Vélez, et al. 2025); cognitive benefits were variable, with some individuals improving after \(\geq\) 10 weeks. Implication for Long COVID: NAD+ depletion may be a shared mechanism; prolonged treatment (\(>\) 10 weeks) may be needed for clinical benefit.
1.3 Treatment Protocols with Translational Potential
- Mitochondrial support: CoQ10 ubiquinol (100–300 mg/day) + NADH (10–20 mg/day), D-ribose (5g TID), acetyl-L-carnitine (500–2000 mg/day), NAD+ precursors (NR 300–1000 mg/day; the only RCT-tested dose is 2000 mg/day (Wu, Guzmán-Vélez, et al. 2025); see Chapter Supplements and Nutraceuticals)
- Mast cell stabilization: Cromolyn sodium, H1+H2 antihistamines, quercetin (for MCAS overlap)
- Low-dose naltrexone: 3–4.5 mg at bedtime for neuroinflammation
- Pacing protocols: Energy envelope management to prevent PEM-like exacerbation Certainty: High for shared mechanisms; Medium for treatment efficacy in Long COVID specifically.
2 Postural Orthostatic Tachycardia Syndrome (POTS)
27–50% of ME/CFS patients meet POTS diagnostic criteria (heart rate increase \(\geq\) 30 bpm upon standing, or HR \(\geq\) 120 bpm, within 10 minutes). The overlap suggests shared autonomic pathophysiology.
2.1 Novel Translational Findings from ME/CFS
Central Catecholamine Deficiency: The NIH intramural study (Walitt et al. 2024) documented reduced CSF dopamine metabolites (DOPA, DOPAC) and norepinephrine metabolites (DHPG) in ME/CFS patients (Walitt et al. 2024). Implication for POTS: Central (not just peripheral) catecholamine deficiency may drive compensatory tachycardia. This suggests catecholamine synthesis support (L-tyrosine, Tetrahydrobiopterin (BH4) cofactors) could be therapeutic.
Chronotropic Incompetence on 2-Day CPET: ME/CFS patients show inadequate heart rate response to exercise workload on Day 2, with autonomic dysfunction (not cardiac pathology) as the primary mechanism (Keller et al. 2024). Implication for POTS: Exercise intolerance in POTS may involve central autonomic dysregulation affecting both HR and metabolic responses.
Hypovolemia and Preload Failure: 10–20% reduction in plasma volume is well-documented in ME/CFS, correlating with orthostatic symptoms (Section blood volume). Implication for POTS: Aggressive blood volume expansion (salt, fluids, fludrocortisone) addresses both conditions.
2.2 Treatment Protocols with Translational Potential
- Catecholamine synthesis support:
- L-tyrosine 1500–3000 mg (morning, empty stomach)
- BH4 cofactor support: Methylfolate 1–5 mg + methylcobalamin 1–5 mg + vitamin C 1000 mg
- Iron optimization (ferritin 100–200 \(\mu\)g/L target)
- Vitamin B6 (P5P 25–50 mg), copper if deficient
- Blood volume expansion: Salt 8–10g/day, fluids 2–3L/day, fludrocortisone 0.1–0.2 mg
- Compression garments: Waist-high compression stockings (20–30 mmHg) + abdominal binders
- Ivabradine: Heart rate control without blood pressure drop (off-label) Certainty: High for hypovolemia and autonomic dysfunction; Medium for central catecholamine deficiency in POTS.
3 Fibromyalgia
Fibromyalgia shares chronic widespread pain, fatigue, sleep disturbance, and exercise intolerance with ME/CFS, with substantial symptom overlap whose estimated magnitude varies widely depending on diagnostic criteria applied.
3.1 Novel Translational Findings from ME/CFS
Small Fiber Neuropathy: Quantitative sensory testing and skin biopsy studies document small fiber dysfunction in a subset of ME/CFS patients, correlating with pain and dysautonomia (Azcue et al. 2023). Implication for Fibromyalgia: Small fiber neuropathy has been documented in fibromyalgia as well (Oaklander et al. 2013). This suggests shared peripheral nerve pathology beyond central sensitization.
Mitochondrial ATP Depletion: Multiple ME/CFS studies show impaired ATP production, early lactate accumulation, and elevated acylcarnitines indicating impaired fatty acid oxidation (Naviaux et al. 2016) (Syed et al. 2025). Implication for Fibromyalgia: Muscle pain and fatigue may reflect energy metabolism failure. Mitochondrial support protocols could address root cause.
Mast Cell Activation: Ketotifen (mast cell stabilizer) was tested in a fibromyalgia Phase 1 RCT but did not show significant benefit at the dose tested (4 mg/day for 8 weeks; \(p = 0.7\) for pain) (Moldofsky et al. 2015). Nevertheless, ME/CFS research provides mechanistic understanding of mast cell–pain–fatigue connections that may warrant further investigation at higher doses. Implication for Fibromyalgia: Mast cell stabilization protocols developed for ME/CFS (cromolyn, quercetin, H1+H2 antihistamines) may benefit fibromyalgia patients with MCAS features.
3.2 Treatment Protocols with Translational Potential
- D-ribose: 5g TID showed improvements across energy, sleep, and well-being in two open-label studies without placebo control (Jacob E. Teitelbaum, Johnson, and St Cyr 2006) (J. E. Teitelbaum et al. 2012); see Chapter Supplements and Nutraceuticals for evidence limitations
- CoQ10 ubiquinol + NADH: CoQ10 100–300 mg/day (300 mg used in fibromyalgia trials (Cordero et al. 2013)) + NADH 10–20 mg/day (combination supported by ME/CFS RCTs (Castro-Marrero et al. 2021); see Chapter Supplements and Nutraceuticals)
- Acetyl-L-carnitine: 500–2000 mg/day for neuroprotection and brain fog reduction (see Chapter Supplements and Nutraceuticals)
- Low-dose naltrexone: 3–4.5 mg at bedtime for neuroinflammation and pain modulation
- NAD+ precursors: NR 300–1000 mg/day (the only RCT-tested dose is 2000 mg/day (Wu, Guzmán-Vélez, et al. 2025)); see Chapter Supplements and Nutraceuticals for full dosing Certainty: Medium for mitochondrial mechanisms; High for mast cell involvement; Medium for small fiber neuropathy overlap.
4 Mast Cell Activation Syndrome (MCAS)
| Key Point | Detail |
|---|---|
| ME/CFS–MCAS co-occurrence | MCAS frequently co-occurs with ME/CFS; the Wirth, Löhn (2023) study (Wirth and Scheibenbogen 2023) provides novel mechanistic understanding of this relationship. |
4.1 Novel Translational Findings from ME/CFS
| Finding | Detail |
|---|---|
| \(\beta\) 2-Adrenergic Receptor Dysfunction as Common Link | Wirth, Löhn (2023) propose that dysfunctional \(\beta\) 2-adrenergic receptors create bidirectional disease worsening: ME/CFS orthostatic stress desensitizes \(\beta\) 2 receptors → mast cell degranulation → mediators worsen orthostatic dysfunction and cerebral hypoperfusion → vicious cycle. Implication for MCAS: \(\beta\) 2-receptor function testing and targeted support may break the cycle. |
| Vascular Pathomechanisms | Histamine and bradykinin both cause vasodilation and vascular permeability, leading to preload failure and orthostatic intolerance. Implication for MCAS: Vascular-focused treatment (beyond antihistamines) may be necessary for patients with prominent orthostatic symptoms. |
| GPCR Autoantibody-Monocyte Reprogramming | Hackel et al. (2025) showed that GPCR autoantibodies don’t just block receptors—they reprogram monocytes to produce inflammatory cytokines (MIP-1\(\delta\), PDGF-BB, TGF-\(\beta\) 3) (Hackel et al. 2025). Implication for MCAS: Autoantibody removal (immunoadsorption) plus monocyte modulation (JAK inhibitors) may be more effective than antihistamines alone. |
4.2 Treatment Protocols with Translational Potential
- H1 + H2 antihistamine combination (H1 alone insufficient):
- Rupatadine 20 mg (triple action: H1 antagonist + PAF antagonist + mast cell stabilizer)
- Or: Loratadine/cetirizine/fexofenadine + famotidine 20–40 mg BID
- Mast cell stabilizers:
- Quercetin 500–1000 mg BID (more effective than cromolyn in vitro)
- Cromolyn sodium 200–400 mg QID (prescription)
- Vitamin C 1000–3000 mg/day
- Amitriptyline: 10–50 mg bedtime (unique mast cell inhibition among antidepressants; reduces IL-8, VEGF, histamine release) Certainty: High for H1+H2 combination; Medium for \(\beta\) 2-receptor mechanism; Low for autoantibody-monocyte pathway in MCAS specifically.
5 Ehlers-Danlos Syndrome (Hypermobile Type)
Hypermobile Ehlers-Danlos Syndrome (hEDS) frequently co-occurs with POTS (70–80%) and MCAS ( 31%), creating a recognized clinical “triad.” However, the pathophysiologic mechanisms linking these conditions remain controversial (Kucharik and Chang 2020).
5.1 Established Mechanisms in EDS
EDS literature documents:
- Structural vascular compliance abnormalities: Collagen defects → vessel stretching → blood pooling → reduced venous return
- Adrenergic hyperresponsiveness: Documented in hEDS cardiovascular autonomic testing (Hakim et al. 2017)
- Mast cell mechanosensitivity: Stretch-activated mast cells via ADGRE2, integrins \(\alpha\)V\(\beta\) 3, \(\alpha\) 5\(\beta\) 1 (Royer and Han 2022)
- Small fiber neuropathy: Common in hEDS, contributing to pain and dysautonomia
5.2 Novel Translational Findings from ME/CFS
The following mechanisms are well-documented in ME/CFS but not yet studied in EDS, representing novel translational opportunities:
- \(\beta\) 2-Adrenergic Receptor Desensitization vs. Hyperresponsiveness:
- EDS literature: Documents adrenergic hyperresponsiveness
- ME/CFS literature: Documents \(\beta\) 2-receptor desensitization from chronic orthostatic stress (Wirth and Scheibenbogen 2023)
- Gap: These may represent different stages or phenotypes. Chronic EDS-related orthostatic stress could lead to eventual desensitization. Research opportunity: Test \(\beta\) 2-receptor function longitudinally in EDS patients to determine if hyperresponsiveness transitions to desensitization.
- Bidirectional MCAS ↔︎ \(\beta\) 2-Receptor Cycle:
| Model | Description |
|---|---|
| Wirth, Löhn (2023) model | Orthostatic stress \(\rightarrow\) \(\beta\) 2-receptor desensitization \(\rightarrow\) mast cell degranulation \(\rightarrow\) mast cell mediators (histamine, PAF) \(\rightarrow\) vascular dysfunction \(\rightarrow\) worse orthostatic stress. |
This cycle has not been studied in EDS, despite clinical recognition of the hEDS-POTS-MCAS triad. Research opportunity: Measure \(\beta\) 2-receptor function in EDS patients with vs. without MCAS to test this model.
- Tetrahydrobiopterin (BH4) Dysregulation:
- ME/CFS findings: Elevated BH4 and BH2 in patients with orthostatic intolerance (Gottschalk et al. 2023) (Bulbule et al. 2024)
- Mechanism: Pentose phosphate pathway activation → BH4 production → iNOS/NO pathway activation → neuroinflammation
- EDS literature: No studies found (2020–2026 search) Research opportunity: Measure BH4 levels in EDS patients with orthostatic intolerance. If elevated, this could explain neuroinflammatory symptoms and provide therapeutic target. Caveat: BH4 research in ME/CFS is very preliminary (n=10–32, single research group). The paradox of elevated BH4 causing dysfunction (rather than deficiency) requires explanation.
- Endothelial (Functional) vs. Structural Vascular Permeability:
- EDS mechanism: Structural collagen weakness → vessel stretching
- ME/CFS mechanism: Receptor-mediated endothelial permeability (vasoactive mediators → functional permeability changes) Research opportunity: Distinguish structural from functional vascular dysfunction in EDS. Patients may have both mechanisms, requiring combined treatment.
- Plasma Cell Autoimmunity: If EDS patients develop post-viral or autoimmune features, plasma cell-targeted therapy (daratumumab) could be considered, following ME/CFS precedent. However, this is entirely speculative for EDS.
5.3 Treatment Protocols with Translational Potential
| Protocol | Rationale | Certainty in EDS |
|---|---|---|
| Evidence Base | POTS management (salt, fluids, compression, fludrocortisone) | Addresses hypovolemia and preload failure |
| High | Well-established | Mast cell stabilization (H1+H2 antihistamines, quercetin, cromolyn) |
| Addresses MCAS in hEDS-MCAS subset | High | Clinical use common |
| Rupatadine (H1 + PAF antagonist + mast cell stabilizer) | Triple mechanism addresses vascular pathomechanisms | Medium |
| ME/CFS evidence, not tested in EDS | Catecholamine synthesis support (L-tyrosine, Tetrahydrobiopterin (BH4) cofactors) | Supports autonomic function if central deficiency present |
| Low-Medium | ME/CFS evidence, not tested in EDS | Pacing and energy envelope management |
| Prevents post-exertional symptom exacerbation | Medium | Reduces injury risk from hypermobility overexertion |
| Mitochondrial support (CoQ10, D-ribose, L-carnitine) | Addresses energy deficit from chronic musculoskeletal compensation | Low-Medium |
| Theoretical, untested in EDS |
5.4 Key Distinctions: EDS-Specific Considerations
While ME/CFS mechanisms translate to EDS, critical differences exist:
- Fatigue source: In EDS, fatigue may result from musculoskeletal compensation for joint instability, not just autonomic/mitochondrial dysfunction
- Exercise intolerance: In EDS, joint subluxations and injury risk limit activity; in ME/CFS, metabolic failure causes PEM
- Pain mechanisms: In EDS, structural joint instability contributes; in ME/CFS, neuroinflammation and central sensitization dominate
- Treatment focus: EDS requires joint protection and physical therapy alongside systemic treatments Not all EDS patients will respond to ME/CFS-derived protocols. Subset with prominent autonomic dysfunction, MCAS, or post-viral features most likely to benefit.
5.5 Research Priorities for EDS
- Longitudinal \(\beta\) 2-receptor function testing: Does hyperresponsiveness transition to desensitization with disease duration?
- Tetrahydrobiopterin (BH4) measurement in EDS with orthostatic intolerance: Is the ME/CFS finding translatable?
- Endothelial biomarkers: Are VWF, fibronectin, thrombospondin elevated in EDS-POTS-MCAS subset?
- Controlled trials of rupatadine: Does PAF antagonism benefit EDS patients with vascular symptoms?
- Autoantibody screening: What percentage of EDS patients have GPCR autoantibodies? Certainty: Medium for vascular mechanisms; Low-Medium for \(\beta\) 2-receptor pathway; Low for Tetrahydrobiopterin (BH4) dysregulation; None for plasma cell autoimmunity. Bottom line: The Wirth 2023 integrated model (MCAS ↔︎ \(\beta\) 2-receptors ↔︎ vascular dysfunction ↔︎ POTS) represents a completely untested but biologically plausible hypothesis for EDS. If validated, it would explain the hEDS-POTS-MCAS triad and provide targeted treatment strategies.